Arcturus Therapeutics Ltd (NASDAQ:ARCT) Given Average Rating of “Buy” by Brokerages

Arcturus Therapeutics Ltd (NASDAQ:ARCT) has earned a consensus recommendation of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $15.33.

ARCT has been the subject of a number of recent research reports. Brookline Capital Management reiterated a “buy” rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 24th. Zacks Investment Research upgraded Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Tuesday, July 16th. ValuEngine cut Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Chardan Capital set a $18.00 price objective on Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Thursday, June 20th. Finally, HC Wainwright lifted their price objective on Arcturus Therapeutics from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Highline Capital Management L.P. boosted its stake in shares of Arcturus Therapeutics by 356.6% in the second quarter. Highline Capital Management L.P. now owns 217,866 shares of the biotechnology company’s stock valued at $2,057,000 after purchasing an additional 170,152 shares during the period. BlackRock Inc. boosted its stake in shares of Arcturus Therapeutics by 23.5% in the second quarter. BlackRock Inc. now owns 23,548 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 4,480 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of Arcturus Therapeutics in the second quarter valued at approximately $128,000. ARK Investment Management LLC boosted its stake in shares of Arcturus Therapeutics by 8.3% in the second quarter. ARK Investment Management LLC now owns 1,004,368 shares of the biotechnology company’s stock valued at $9,481,000 after purchasing an additional 77,224 shares during the period. Finally, Nikko Asset Management Americas Inc. boosted its stake in shares of Arcturus Therapeutics by 102.8% in the second quarter. Nikko Asset Management Americas Inc. now owns 129,974 shares of the biotechnology company’s stock valued at $1,227,000 after purchasing an additional 65,875 shares during the period. Institutional investors own 13.25% of the company’s stock.

Arcturus Therapeutics stock traded up $1.76 during midday trading on Tuesday, reaching $10.56. 176,800 shares of the company were exchanged, compared to its average volume of 129,450. The company has a market capitalization of $125.61 million, a price-to-earnings ratio of -4.89 and a beta of 2.36. The firm’s 50-day simple moving average is $10.32 and its 200-day simple moving average is $7.41. Arcturus Therapeutics has a 1 year low of $4.11 and a 1 year high of $15.50. The company has a debt-to-equity ratio of 2.43, a quick ratio of 2.51 and a current ratio of 2.51.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, August 15th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.46. The firm had revenue of $10.15 million during the quarter, compared to analysts’ expectations of $4.01 million. Arcturus Therapeutics had a negative return on equity of 112.75% and a negative net margin of 50.32%. On average, analysts forecast that Arcturus Therapeutics will post -2.17 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Featured Article: What is the Quick Ratio?

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.